This event is archived. Final snapshot from when the story concluded. View on Dashboard
Events / Regulatory / UK Bans Misleading Supplement Ads
Regulatory advertising ban

UK Bans Misleading Supplement Ads

Analysis based on 6 articles · First reported Mar 25, 2026 · Last updated Mar 25, 2026

Sentiment
-10
Attention
2
Articles
6
Market Impact
General
Live prominence charts, article sentiment distribution, and event development timeline available on the Ergen Dashboard
Market Impact

The ban on misleading health supplement ads by the United Kingdom — Advertising Standards Authority could negatively impact the sales and reputation of the involved companies like NDN Collective, Lunera, MinervaX, Nova Menopause Vitality, and PolyBiotics. This event highlights increased regulatory scrutiny in the nutraceutical and advertising industries, potentially leading to stricter compliance requirements and a shift towards more transparent marketing practices across the sector.

Nutraceutical Advertising
Event Summary

The United Kingdom — Advertising Standards Authority has banned five adverts for health supplements from brands including 222 Balance Me (by NDN Collective), Lunera, MinervaX, Nova Menopause Vitality, and PolyBiotics. The ads were found to be making misleading claims about treating symptoms of menopause, polycystic ovarian syndrome (PCOS), and other women's hormonal issues. The United Kingdom — Advertising Standards Authority's decision followed an AI-powered sweep of online health claims, revealing widespread issues with misleading advertising. While NDN Collective (associated with Celebrity Big Brother (British TV series) series 13), Lunera, and PolyBiotics acknowledged their inappropriate claims and are working with The Standard (London newspaper) for compliance, MinervaX and Nova Menopause Vitality did not respond to inquiries. This action underscores the United Kingdom — Advertising Standards Authority's commitment to ensuring clear and accurate information in women's health advertising.

Entities Involved
govactor
United Kingdom — Advertising Standards Authority
The United Kingdom — Advertising Standards Authority banned five adverts for health supplements due to misleading claims, reinforcing its role in consumer protection.
Importance 90.0 Sentiment 20.0
ngo
NDN Collective
NDN Collective, a small business, had its 222 Balance Me product ads banned for implying treatment of menopause symptoms. The company acknowledged the issue and is working with The Standard (London newspaper).
Importance 70.0 Sentiment -30.0
priv
Lunera
Lunera's food supplement ads were banned for making medicinal claims. The company accepted that its claims were inappropriate.
Importance 60.0 Sentiment -30.0
oth
PolyBiotics
PolyBiotics' ads and website were banned for implying their food supplements could treat PCOS. The company accepted that its claims constituted disease treatment claims.
Importance 60.0 Sentiment -30.0
oth
Nova Menopause Vitality
Nova Menopause Vitality's ads were banned for claiming to treat menopause symptoms. The company did not respond to the United Kingdom — Advertising Standards Authority's inquiries.
Importance 50.0 Sentiment -40.0
per
Celebrity Big Brother (British TV series) series 13
Celebrity Big Brother (British TV series) series 13 is associated with NDN Collective, whose product 222 Balance Me had ads banned. She defended the company as a small business learning regulations.
Importance 30.0 Sentiment -20.0
priv
The Standard (London newspaper)
NDN Collective is working with The Standard (London newspaper) to ensure compliance with advertising regulations after its ads were banned.
Importance 20.0 Sentiment 10.0
ERGEN INTELLIGENCE
Track this event live

Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.